Skip to main content

Join us in setting the next phase of Alzheimer’s research strategy

Dr. Richard Hodes
Richard HODES,
Director,
Office of the Director (OD)
.
Eliezer Masliah
Eliezer MASLIAH,
Director,
Division of Neuroscience (DN)
.

Driven by an ambitious national goal to treat or prevent Alzheimer’s disease by 2025, funding and progress in research have expanded dramatically in the six years since the first NIH Alzheimer’s Research Summit. We have known for many years that a disease as heterogeneous as Alzheimer’s is not likely to yield to a single, all-encompassing solution. Today, we seek a precision medicine approach to treatment and prevention—the ability to develop interventions that can address the underlying disease process and be tailored to a person’s unique disease risk profile. Now, with increased funding, technological advances, and the new programs launched since 2012, we are beginning to realize that goal. 

On March 1 and 2, we’ll come together for the 2018 NIH Alzheimer's Research Summit, the third such meeting, to assess the progress we’ve made and set the course for the next few years. We hope you’ll join us for this key strategic planning meeting, in person on the NIH campus in Bethesda, Maryland or via videocast. A wide range of stakeholders, including government, industry, academia, private foundations, and patient advocates, will participate, to continue the development of a growing research enterprise that can deliver effective therapies for patients at all stages of the disease.

A hallmark of this and previous Summits is hearing from a broad range of diverse innovators and thinkers working on Alzheimer’s and many other complex diseases, who will highlight major advances and discuss critical issues on seven major topics:

  • Novel mechanistic insights into the complex biology and heterogeneity of Alzheimer’s
  • Enabling precision medicine for Alzheimer’s disease
  • Translational tools and infrastructure to enable predictive drug development
  • Emerging therapeutics
  • Understanding the impact of the environment to advance disease prevention
  • Advances in disease monitoring, assessment and care
  • Building an open science research ecosystem to accelerate Alzheimer’s therapy development

Throughout, speakers and panelists will address research needs and opportunities to understand disease heterogeneity; enhance research rigor, reproducibility, and translatability; and enable rapid translational learning through open science.

Building on a firm foundation to chart the future of Alzheimer’s research

The previous Alzheimer’s Research Summits in 2012 and 2015 resulted in recommendations that served as the basis for developing research implementation milestones. These milestones detailed the steps and success criteria for the NIH and other stakeholders toward the development of effective treatment and prevention for Alzheimer’s. The milestones encompass the entire research landscape and serve as the basis for the development of the NIH Alzheimer's Disease Bypass Budget.

We expect the next generation of research recommendations to emerge from the 2018 Summit, pointing the way toward enabling precision medicine for Alzheimer’s treatment and prevention.

You can learn more about the 2018 NIH Alzheimer’s Disease Research Summit, including the full agenda and links to register at: https://www.nia.nih.gov/research/nih-ad-summit-2018-program-agenda.

We look forward to an engaging and groundbreaking meeting. Please join us!

Comments

Submitted by Gary Frank Scott PhD on February 14, 2018

Why is not the cause of oligomerization not given more study, since the pathology is related mostly to that deteriorating event?

Protein polymorphism, misfolding, oligomerization, and (pathogenic) aggregation (intracellular and extracellular) in brain is an active area of research focus. NIA recently released Funding Opportunity Announcements that address this research focus (RFA-AG-18-025) as well as basic research on the etiology (or causes) of Alzheimer’s Disease (AD) (see https://www.nia.nih.gov/ad-foas). We are actively seeking grant applications on the basic science of AD.

Add new comment

Your e-mail address will not be posted.
About text formats

Plain text

  • Allowed HTML tags: <p> <br>
  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.